Rongyao Chen

Title: Innovations of Rongyao Chen in Pharmaceutical Chemistry

Introduction

Rongyao Chen is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as Bruton's tyrosine kinase inhibitors. With a total of 2 patents, his work focuses on innovative solutions for treating various diseases.

Latest Patents

Rongyao Chen's latest patents include two significant inventions. The first patent is titled "Aminonorbornane derivative and manufacture method therefor and use thereof." This invention relates to a compound of formula I or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorph, an ester, an optical isomer, or a prodrug thereof. It also includes a pharmaceutical composition comprising the compound of formula I, which is used as a Bruton's tyrosine kinase inhibitor with high selectivity for the BTK(C481S) mutant. This compound is aimed at preventing or treating heteroimmune diseases, autoimmune diseases, or cancer.

The second patent is "Substituted imidazo[1,5-a]pyrazines as Bruton's tyrosine kinase inhibitors." Similar to the first, this invention also relates to a compound of formula I or its derivatives. It serves as a Bruton's tyrosine kinase inhibitor with high selectivity for the BTK(C481S) mutant, contributing to the development of medicaments for treating various diseases.

Career Highlights

Rongyao Chen has worked with several companies throughout his career. Notably, he has been associated with Transthera Sciences (Nanjing), Inc. and Transthera Sciences, Inc. His experience in these organizations has allowed him to further his research and development in pharmaceutical innovations.

Collaborations

Due to space constraints, the details of collaborations will not be included.

Conclusion

Rongyao Chen's contributions to pharmaceutical chemistry through his innovative patents highlight his role as a significant inventor in the field. His work on Bruton's tyrosine kinase inhibitors showcases the potential for advancements in treating serious health conditions.